Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(10%)
Results Posted
50%(1 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_1
1
10%
Ph phase_3
1
10%
Ph phase_4
8
80%

Phase Distribution

1

Early Stage

0

Mid Stage

9

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 3Large-scale testing
1(10.0%)
Phase 4Post-market surveillance
8(80.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)
Other(6)

Detailed Status

unknown6
Completed2
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (10.0%)
Phase 31 (10.0%)
Phase 48 (80.0%)

Trials by Status

completed220%
unknown660%
terminated110%
recruiting110%

Recent Activity

1 active trials
Showing 5 of 10
recruitingphase_4

Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention

NCT06228456
completedphase_4

Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI

NCT04483583
unknownphase_4

A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients

NCT04255602
unknownphase_1

De-escalation of Ticagrelor in Post PPCI

NCT05831462
unknownphase_3

Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome

NCT04718025
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT06228456Phase 4

Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention

Recruiting
NCT04483583Phase 4

Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI

Completed
NCT04255602Phase 4

A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients

Unknown
NCT05831462Phase 1

De-escalation of Ticagrelor in Post PPCI

Unknown
NCT04718025Phase 3

Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome

Unknown
NCT05283356Phase 4

Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation

Unknown
NCT04331145Phase 4

Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation

Completed
NCT05210595Phase 4

Optimal Dosage of Ticagrelor in Korean Patients With AMI

Unknown
NCT04734353Phase 4

Prasugrel 5 mg vs. Ticagrelor 60 mg in CHIP (E5TION)

Unknown
NCT03224923Phase 4

A Novel Strategy For Personalized Long-Term Dual Antiplatelet Therapy (RAPID EXTEND PILOT STUDY)

Terminated

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10